Suppr超能文献

新型青光眼手术:美国眼科学会报告。

Novel glaucoma procedures: a report by the American Academy of Ophthalmology.

机构信息

University of Southern California, Los Angeles, CA, USA.

出版信息

Ophthalmology. 2011 Jul;118(7):1466-80. doi: 10.1016/j.ophtha.2011.03.028.

Abstract

OBJECTIVE

To review the published literature and summarize clinically relevant information about novel, or emerging, surgical techniques for the treatment of open-angle glaucoma and to describe the devices and procedures in proper context of the appropriate patient population, theoretic effects, advantages, and disadvantages.

DESIGN

Devices and procedures that have US Food and Drug Administration clearance or are currently in phase III clinical trials in the United States are included: the Fugo blade (Medisurg Ltd., Norristown, PA), Ex-PRESS mini glaucoma shunt (Alcon, Inc., Hunenberg, Switzerland), SOLX Gold Shunt (SOLX Ltd., Boston, MA), excimer laser trabeculotomy (AIDA, Glautec AG, Nurnberg, Germany), canaloplasty (iScience Interventional Corp., Menlo Park, CA), trabeculotomy by internal approach (Trabectome, NeoMedix, Inc., Tustin, CA), and trabecular micro-bypass stent (iStent, Glaukos Corporation, Laguna Hills, CA).

METHODS

Literature searches of the PubMed and the Cochrane Library databases were conducted up to October 2009 with no date or language restrictions.

MAIN OUTCOME MEASURES

These searches retrieved 192 citations, of which 23 were deemed topically relevant and rated for quality of evidence by the panel methodologist. All studies but one, which was rated as level II evidence, were rated as level III evidence.

RESULTS

All of the devices studied showed a statistically significant reduction in intraocular pressure and, in some cases, glaucoma medication use. The success and failure definitions varied among studies, as did the calculated rates. Various types and rates of complications were reported depending on the surgical technique. On the basis of the review of the literature and mechanism of action, the authors also summarized theoretic advantages and disadvantages of each surgery.

CONCLUSIONS

The novel glaucoma surgeries studied all show some promise as alternative treatments to lower intraocular pressure in the treatment of open-angle glaucoma. It is not possible to conclude whether these novel procedures are superior, equal to, or inferior to surgery such as trabeculectomy or to one another. The studies provide the basis for future comparative or randomized trials of existing glaucoma surgical techniques and other novel procedures.

摘要

目的

回顾已发表的文献,总结新型或新兴的治疗开角型青光眼的手术技术的临床相关信息,并在适当的患者人群、理论效果、优点和缺点的背景下描述这些设备和程序。

设计

纳入了美国食品和药物管理局(FDA)批准的或正在美国进行 III 期临床试验的设备和程序:Fugo 刀片(Medisurg Ltd.,诺里斯敦,宾夕法尼亚州)、Ex-PRESS 微型青光眼分流器(爱尔康公司,Hunenberg,瑞士)、SOLX Gold Shunt(SOLX Ltd.,波士顿,马萨诸塞州)、准分子激光小梁切开术(AIDA,Glautec AG,纽伦堡,德国)、内路小梁切开术(iScience Interventional Corp.,门洛帕克,加利福尼亚州)、经内路小梁切开术(Trabectome,NeoMedix,Inc.,塔斯汀,加利福尼亚州)和小梁微旁路支架(iStent,Glaukos Corporation,拉古纳山,加利福尼亚州)。

方法

对 PubMed 和 Cochrane 图书馆数据库进行了截至 2009 年 10 月的文献检索,没有日期或语言限制。

主要观察指标

这些检索共获得 192 篇参考文献,其中 23 篇被认为与主题相关,并由小组方法学家对证据质量进行了评分。除了一项被评为 II 级证据的研究外,所有的研究都被评为 III 级证据。

结果

所有研究的设备都显示出眼压有统计学意义的降低,并且在某些情况下,减少了青光眼药物的使用。研究的成功和失败的定义各不相同,计算出的比率也不同。不同类型和比率的并发症取决于手术技术。根据文献回顾和作用机制,作者还总结了每种手术的理论优缺点。

结论

研究中的新型青光眼手术都显示出作为替代治疗方法的潜力,可降低开角型青光眼的眼压。目前尚不能确定这些新型手术是否优于、等同于或劣于小梁切除术或彼此之间。这些研究为现有的青光眼手术技术和其他新型手术的未来比较或随机试验提供了基础。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验